VCI Wealth Management LLC Buys 406 Shares of Danaher Co. (NYSE:DHR)

VCI Wealth Management LLC boosted its stake in shares of Danaher Co. (NYSE:DHR) by 5.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,422 shares of the conglomerate’s stock after acquiring an additional 406 shares during the quarter. VCI Wealth Management LLC’s holdings in Danaher were worth $1,933,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Fort Pitt Capital Group LLC grew its holdings in Danaher by 3.2% during the 3rd quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock worth $66,194,000 after acquiring an additional 7,421 shares during the last quarter. Good Life Advisors LLC acquired a new position in Danaher during the 3rd quarter valued at about $217,000. ORG Partners LLC lifted its position in Danaher by 1,212.8% during the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after purchasing an additional 2,559 shares during the period. Harvest Portfolios Group Inc. lifted its position in Danaher by 1.2% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after purchasing an additional 2,465 shares during the period. Finally, Stifel Financial Corp lifted its position in Danaher by 1.3% during the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after purchasing an additional 11,216 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $250.51 on Tuesday. The stock has a market capitalization of $180.94 billion, a P/E ratio of 47.81, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70. The company has a 50 day moving average of $235.33 and a 200-day moving average of $253.62. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Ratings Changes

DHR has been the topic of a number of research reports. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research report on Friday, December 13th. Guggenheim started coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Robert W. Baird cut their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, Barclays cut their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.